JP2014062109A5 - - Google Patents

Download PDF

Info

Publication number
JP2014062109A5
JP2014062109A5 JP2013246532A JP2013246532A JP2014062109A5 JP 2014062109 A5 JP2014062109 A5 JP 2014062109A5 JP 2013246532 A JP2013246532 A JP 2013246532A JP 2013246532 A JP2013246532 A JP 2013246532A JP 2014062109 A5 JP2014062109 A5 JP 2014062109A5
Authority
JP
Japan
Prior art keywords
component
weight
use according
salts
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013246532A
Other languages
Japanese (ja)
Other versions
JP2014062109A (en
JP5766258B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2013246532A priority Critical patent/JP5766258B2/en
Priority claimed from JP2013246532A external-priority patent/JP5766258B2/en
Publication of JP2014062109A publication Critical patent/JP2014062109A/en
Publication of JP2014062109A5 publication Critical patent/JP2014062109A5/ja
Application granted granted Critical
Publication of JP5766258B2 publication Critical patent/JP5766258B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

色素沈着予防及び改善用の化粧料、外用医薬品又は医薬部外品を製造するための、下記（Ａ）成分及び（Ｂ）成分の使用；
（Ａ）アデノシン５’−一リン酸及びその塩よりなる群から選択される少なくとも１種、
（Ｂ）エラグ酸、４−アルキルレゾルシノール、トラネキサム酸、及びこれらの塩、カミツレエキス、ならびにユビキノンよりなる群から選択される少なくとも１種。 Use of the following (A) component and (B) component for manufacturing the cosmetics for prevention and improvement of pigmentation , an external pharmaceutical, or a quasi-drug ;
(A) at least one selected from the group consisting of adenosine 5′-monophosphate and salts thereof;
(B) At least one selected from the group consisting of ellagic acid, 4-alkylresorcinol, tranexamic acid, and salts thereof, chamomile extract, and ubiquinone. （Ｂ）成分がエラグ酸、４−アルキルレゾルシノール、トラネキサム酸、及びこれらの塩よりなる群から選択される少なくとも１種の場合、（Ｂ）成分は前記（Ａ）成分の総重量１重量部に対して０．１〜１００重量部、（Ｂ）成分がカミツレエキスの場合、（Ｂ）成分は前記（Ａ）成分の総重量１重量部に対して０．０００１〜１０重量部、（Ｂ）成分がユビキノンの場合、（Ｂ）成分は前記（Ａ）成分の総重量１重量部に対して０．００１〜１００重量部である、請求項１に記載の使用。 When component (B) is at least one selected from the group consisting of ellagic acid, 4-alkylresorcinol, tranexamic acid, and salts thereof, component (B) is added in a total weight of 1 part by weight of component (A). When the component (B) is a chamomile extract, the component (B) is 0.0001 to 10 parts by weight with respect to 1 part by weight of the total component (A), (B) The use according to claim 1, wherein when the component is ubiquinone, the component (B) is 0.001 to 100 parts by weight with respect to 1 part by weight of the total weight of the component (A) . 更に（Ｃ）アルコールが用いられる、請求項１または２に記載の使用。The use according to claim 1 or 2, further comprising (C) an alcohol. 化粧料、外用医薬品又は医薬部外品において前記（Ａ）成分が０．１〜７重量％含有されてなる、請求項１〜３のいずれかに記載の使用。The use according to any one of claims 1 to 3, wherein the component (A) is contained in an amount of 0.1 to 7% by weight in a cosmetic, an external medicine or a quasi drug. 化粧料、外用医薬品又は医薬部外品において前記（Ｂ）成分が０．０００１〜５０重量％含有されてなる、請求項１〜４のいずれかに記載の使用。 The use according to any one of claims 1 to 4 , wherein the component (B) is contained in an amount of 0.0001 to 50% by weight in cosmetics, external medicines or quasi drugs .
JP2013246532A 2004-09-22 2013-11-28 Pigmentation preventing or improving agent Active JP5766258B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013246532A JP5766258B2 (en) 2004-09-22 2013-11-28 Pigmentation preventing or improving agent

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004274454 2004-09-22
JP2004274454 2004-09-22
JP2004376562 2004-12-27
JP2004376562 2004-12-27
JP2013246532A JP5766258B2 (en) 2004-09-22 2013-11-28 Pigmentation preventing or improving agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012144388A Division JP5514268B2 (en) 2004-09-22 2012-06-27 Pigmentation preventing or improving agent

Publications (3)

Publication Number Publication Date
JP2014062109A JP2014062109A (en) 2014-04-10
JP2014062109A5 true JP2014062109A5 (en) 2014-05-22
JP5766258B2 JP5766258B2 (en) 2015-08-19

Family

ID=47011852

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012144388A Active JP5514268B2 (en) 2004-09-22 2012-06-27 Pigmentation preventing or improving agent
JP2013246532A Active JP5766258B2 (en) 2004-09-22 2013-11-28 Pigmentation preventing or improving agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012144388A Active JP5514268B2 (en) 2004-09-22 2012-06-27 Pigmentation preventing or improving agent

Country Status (1)

Country Link
JP (2) JP5514268B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5514268B2 (en) * 2004-09-22 2014-06-04 大塚製薬株式会社 Pigmentation preventing or improving agent
JP6430109B2 (en) * 2012-11-02 2018-11-28 ロート製薬株式会社 Composition for external use
JP6057697B2 (en) * 2012-12-25 2017-01-11 株式会社マンダム Emulsion composition for skin
JP6166544B2 (en) * 2013-02-13 2017-07-19 第一三共ヘルスケア株式会社 Preventive or therapeutic agent for pigmentation disease
JP6180816B2 (en) * 2013-06-24 2017-08-16 ポーラ化成工業株式会社 Topical skin preparation
JP7307685B2 (en) * 2018-01-31 2023-07-12 大塚製薬株式会社 Method for suppressing discoloration of topical composition containing adenosine phosphate and tranexamic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5514268B2 (en) * 2004-09-22 2014-06-04 大塚製薬株式会社 Pigmentation preventing or improving agent
JP5093998B2 (en) * 2004-09-22 2012-12-12 大塚製薬株式会社 Pigmentation preventing or improving agent

Similar Documents

Publication Publication Date Title
JP2014062109A5 (en)
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112015014372A2 (en) autotaxin inhibitors
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
JP2015078230A5 (en)
IL235020A0 (en) N-phenyl benzenesulfonamide derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
CL2016002132A1 (en) Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
HRP20191523T1 (en) Spirocyclic isoxazoline parasiticidal combinations
BR112014014262A2 (en) nanoparticles; pharmaceutical composition; method of administering one or more therapeutic, prophylactic, and / or diagnostic agents to a patient in need thereof and method of preparing the particles.
CL2014002757A1 (en) Compounds derived from benzamide to inhibit the activity of abl1, abl2 and bcr-abl1, pharmaceutical composition; and use in the treatment of cancer.
JP2013014622A5 (en)
EA201500742A1 (en) PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
IL232764A (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease
JP2014218522A5 (en)
JP2015525757A5 (en)
BR112015017251A8 (en) pharmaceutical compositions comprising nitroxil donors, mixtures and uses of said pharmaceutical compositions
UA111415C2 (en) Pharmaceutical preparation containing dihydroquinazoline derivative possessing antiviral activity
BR112015001207A8 (en) carbamate / urea derivatives, their uses, pharmaceutical composition, free form and their method of preparation
RU2017141536A (en) SUBSTITUTED INDOL-5-OLA DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
WO2016040814A3 (en) Disulfide polymers and methods of use
JP2014533256A5 (en)
HK1219063A1 (en) Pharmaceutical compositions containing hyaluronic acid for use in the treatment of black disk disease
JP2011157392A5 (en)
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
JP2015500340A5 (en)